Drug Approval | February 01, 2024
Orchid Pharma's Exblifeb granted EMA approval
Exblifeb demonstrates remarkable efficacy in treating complicated Urinary Tract Infections (cUTI), pneumonia
Exblifeb demonstrates remarkable efficacy in treating complicated Urinary Tract Infections (cUTI), pneumonia
Pivotal trial found the enfortumab vedotin plus pembrolizumab combination significantly extended overall and progression-free survival
The registered capital of the newly founded company is € 50 million
GC1130A has previously achieved notable milestones by securing both RPDD and ODD from the U.S. FDA in January 2023
Produodopa is the first-and-only subcutaneous 24-hour infusion of levodopa-based therapy for the treatment of severe motor fluctuations
Glenmark Life Sciences will manufacture API in the therapeutic area of urinary anti-spasmodic, to supply to the global innovator
Bayer has granted the non-exclusive rights to Sun Pharma to market and distribute a second brand of Finerenone under the brand name Lyvelsa
Sonoma will manufacture Ocudox by Avenova with packaging similar to NovaBay’s Avenova products
Shivalik Rasayan Limited have successfully submitted USMDF for API " Palbociclib " to USFDA
Varenicline Tablets (RLD Chantix) had estimated annual sales of US $412 million in the US
Subscribe To Our Newsletter & Stay Updated
